Intact Genomics Intellectual Property Information

On September 25th, 2019, the United States Patent and Trademark Office (USPTO) issued a new patent of “Fungal Artificial Chromosomes, Compositions, Methods and Uses Therefor” (U.S. Patent No. 10,337,019) to Intact Genomics, Inc. The patent covers Fungal artificial chromosome (FAC) vectors which can be replicated in a bacterial or a fungal host and can comprise an insert of heterologous DNA up to 300-500 kilobases into a fungal genome. The insert sequence can be modified by homologous recombination. Fungal artificial chromosome (FAC) vectors also can be a plasmid comprising bacterial and fungal origins of replication, as well as bacterial and fungal selection marker genes. Additionally, the patent discloses the methods of generating plasmid libraries including vectors comprising intact SM gene clusters.

On April 7, 2022, China National Intellectual Property Administration (国家知识产权局) issued a patent of “Fungal Artificial Chromosomes, Compositions, Methods and Uses Therefor”(真菌人工染色体、组成、方法和用途)  to Intact Genomics, Inc. China Paten No. 201710302226.0. The fungal artificial chromosomes technology has broad application prospects in many fields, such as new medicinal materials discovery, agricultural development, and environmental protection.

Intact Genomics owns the following registered trademarks granted by the United States Patent and Trademark Office (USPTO):
Intact Genomics®, IG®, ig®, igTherapeutics®, FastAmp®, i7®, DirectPlate®    

This website and all Intact Genomics marketing materials are copyrighted publication of Intact Genomics, Inc. All rights are reserved.

Intact Genomics obtained a Non-exclusive license to U.S. Patent Number 7723077 “In Vitro Recombination Method” from Codex DNA (Synthetic Genomics).

Use Restrictions
Intact Genomics’ products are for research or laboratory use only. Inquiries related to additional uses of Intact Genomics’ products are welcomed. Persons using the products should be technically qualified as defined in 40 C.F.R. § 720.3(ee) and should follow the Guidelines for Research involving Recombinant DNA Molecules (N.I.H. Guidelines) as presented in the Federal Register, July 5, 1994 (59 FR 34496) and any amendments thereto. The supply of all products and services are subject to Intact Genomics’ standard Warranty and Limit of Liability. Intact Genomics does not agree to and is not bound by any other terms or conditions; unless those terms or conditions have been expressly agreed to in writing by a duly authorized officer of Intact Genomics.

Financial Conflict of Interest (FCOI) Policy
Intact Genomics is dedicated to maintaining ethical integrity of our research-relates activities. Intact Genomics requires Principal Investigators (PIs) and Key Personnel on a sponsored project to disclose a listing of significant financial interests that could be reasonably expected to bias the design, conduct, or reporting of the project. For more information and our full policy, please click IG FCOI Policy.